Hormone Replacement Therapy: Risks and Benefits
PDF

Keywords

Hormone Replacement Therapy
Menopause
Therapeutic resources

How to Cite

1.
Gomes Lima L, Munir Tayfour N, Oliveira Lemos PC, Freitas Alves M, Mota Ferreira I, Vieira Gomes E. Hormone Replacement Therapy: Risks and Benefits. Integr J Med Sci [Internet]. 2020Nov.3 [cited 2021Mar.6];7. Available from: https://mbmj.org/index.php/ijms/article/view/242

Abstract

The climacteric is a physiological period of the female reproductive cycle characterized by a decrease in the levels of sex hormones, mainly estrogen. It consists of several phases, with amenorrhea as the initial clinical manifestation followed by long-term changes, such as vaginal atrophy. In this context, hormone replacement therapy (HRT) aims to improve the symptoms of female reproductive senescence, seeking to provide a comfortable physical and psychological condition during this period. However, as with any drug treatment, HRT has its risks and benefits, and it is up to the medical practitioner, in agreement with the patient, looking for the best therapeutic option, minimizing the risks and consequences resulting from this clinical approach.

https://doi.org/10.15342/ijms.7.242
PDF

References

Gass M. (2008) Highlights from the latest WHI publications and the latest North American Menopause Society position statement on use of menopausal hormone therapy. Cleve Clin J Med [Supplement];75 Supplement 4: S13–S16

The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728-753.

Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, et al. (2015) Treatment of symptoms of the menopause: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 100: 3975–4011

Benkhadra K, Mohammed K, Al Nofal A, Carranza Leon BG, Alahdab F, et al. (2015) Menopausal hormone therapy and mortality: A systematic review and meta-analysis. J Clin Endocrinol Metab 100: 4021–4028.

Serpa MA, Lima AA, Guimarães ACP, Carrilo MRGG, Coura-Vital W, Veloso VM. (2016) Fatores associados à qualidade de vida em mulheres no climatério. Reprod Clim 31: 76–81

Rozenberg S, Bruyère O, Bergmann P, Cavalier E, Gielen E, Goemaere S, et al. (2020) How to manage osteoporosis before the age of 50. Maturitas 138: 14–25

Minkin MJ. (2019) Menopause: Hormones, lifestyle, and optimizing aging. Obstet Gynecol Clin North Am 46: 501–514.

Fonseca AM, Bagnoli VR, Aldrighi JM, Junqueira PAA (2001) Esquemas de terapia hormonal no climatéri Rev Assoc Med Bras 47: 1-5.

Utian WH, Archer DF, Bachmann GA, Gallagher C, Grodstein Fn, et al. (2008) Estrogen and progestogen use in postmenopausal women: July 2008 position statement of the North American Menopause Society. Menopause 15: 584–602

Practice Committee of the American Society for Reproductive Medicine. Estrogen and progestogen therapy in postmenopausal women. (2008) Fertil Steril 90: S88–102

Aidelsburger P, Schauer S, Grabein K, Wasem J. (2012) Alternative methods for the treatment of post-menopausal troubles. GMS Health Technol Assess 8

Ferreira VN, Chinelato RSC, Castro MR, Ferreira MEC (2013) Menopausa: marco biopsicossocial do envelhecimento feminino. Psicologia & Sociedade 25(2): 410-419

Pitkin J. Alternative and Complementary therapies for the menopause. (2012) Menopause Int 18: 20–27

Villiers TJ, Gass MLS, Haines CJ, Hall JE, Lobo RA, Pierroz DD, et al. (2013) Global consensus statement on menopausal hormone therapy. Climacteric 16: 203-204

Villiers TJ, Pines A, Panay N, Gambacciani M, Archer DF, Baber RJ, et al. (2013) Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 16: 316–337

Sood R, Faubion SS, Kuhle CL, Thielen JM, Shuster LT. (2014) Prescribing menopausal hormone therapy: An evidence-based approach. Int J Womens Health 6: 47–57

Wender MCO, Pompei LM, Fernandes CE. (2014) Consenso Brasileiro de Terapêutica Hormonal na Menopausa. Associação Brasileira de Climatério (SOBRAC), São Paulo.

American Association of Clinical Endocrinologists; American College of Endocrinology Clinical practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis. (2020)

Goldstein I, Dicks B, Kim NN, Hartzell R. (2013) Multidisciplinary overview of vaginal atrophy and associated genitourinary symptoms in postmenopausal women. Sex Med 1: 44–53

Lindsay R, Aitken JM, Anderson LB, Hart DM, Macdonald EB, et al. (1976) Long-term prevention of postmenopausal osteoporosis by œstrogen. Lancet 307: 1038–1041

Gambacciani M, Monteleone P, Sacco A, Genazzani AR. (2003) Hormone replacement therapy and endometrial, ovarian and colorectal cancer. Best Pract Res Clin Endocrinol Metab 17: 139–147

Lacey JV, Brinton LA, Lubin JH, Sherman ME, Schatzkin A, et al. (2005) Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev 14: 1724–1731

Camargos AL, do Nascimento Ed. (2009) Terapia de reposição hormonal e desempenho cognitivo na Terceira idade. Estud Psicol (Campinas) 26: 437–443

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2020 Lima LG et al.